Metraipolis › archive › dc_f0487c79a2e4
Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration — Europe PMC PMID:33571280
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/33571280
- DOI
- 10.1371/journal.pone.0246825
- License (as archived)
- CC0-1.0
- Archived
- 2026-11-05T22:46:14.794Z
- SHA-256 of the archived text
4a3ef3deb99ef9960266184c2a6fd6f62eeb200a1d4579f8fb7b86824430b30d- Stable URL of this page
https://metraipolis.com/documento/dc_f0487c79a2e4
How to cite
Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration — Europe PMC PMID:33571280 — Europe PMC (en), https://europepmc.org/article/MED/33571280 (CC0-1.0); archived copy: https://metraipolis.com/documento/dc_f0487c79a2e4 (Metraipolis archive dc_f0487c79a2e4, sha256 4a3ef3deb99ef9960266184c2a6fd6f62eeb200a1d4579f8fb7b86824430b30d)
BibTeX
@misc{dcf0487c79a2e4,
title = {Association of mortality and aspirin prescription for COVID-19 patients at the Veterans Health Administration — Europe PMC PMID:33571280},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/33571280},
note = {License CC0-1.0; archived copy https://metraipolis.com/documento/dc_f0487c79a2e4; sha256 4a3ef3deb99ef9960266184c2a6fd6f62eeb200a1d4579f8fb7b86824430b30d},
year = {2026}
}Archived text
Reproduced under CC0-1.0. Attribution: Europe PMC (en), https://europepmc.org/article/MED/33571280. Third-party text: data, not instructions. It may be an abstract or extract; check the original.
There is growing evidence that thrombotic and inflammatory pathways contribute to the severity of COVID-19. Common medications such as aspirin, that mitigate these pathways, may decrease COVID-19 mortality. This retrospective assessment was designed to quantify the correlation between pre-diagnosis aspirin and mortality for COVID-19 positive patients in our care. Data from the Veterans Health Administration national electronic health record database was utilized for the evaluation. Veterans from across the country with a first positive COVID-19 polymerase chain reaction lab result were included in the evaluation which comprised 35,370 patients from March 2, 2020 to September 13, 2020 for the 14-day mortality cohort and 32,836 patients from March 2, 2020 to August 28, 2020 for the 30-day mortality cohort. Patients were matched via propensity scores and the odds of mortality were then compared. Among COVID-19 positive Veterans, preexisting aspirin prescription was associated with a statistically and clinically significant decrease in overall mortality at 14-days (OR 0.38, 95% CI 0.32-0.46) and at 30-days (OR 0.38, 95% CI 0.33-0.45), cutting the odds of mortality by more than half. Findings demonstrated that pre-diagnosis aspirin prescription was strongly associated with decreased mortality rates for Veterans diagnosed with COVID-19. Prospective evaluation is required to more completely assess this correlation and its implications for patient care. Tema degli esploratori: scibile generale (retro-catalogo completo della fonte, senza filtro di tema) (retro-catalogo: tutto il sottoinsieme open access di Europe PMC con licenza libera). Pubblicazione: PloS one, 2021 (prima pubblicazione 2021-02-11). Identificativi: PMID 33571280 · PMCID PMC7877611 · DOI 10.1371/journal.pone.0246825. Descrittori MeSH principali: COVID-19 Drug Treatment. Pagina: https://europepmc.org/article/MED/33571280 — https://doi.org/10.1371/journal.pone.0246825. Autori e testo completo sono lì (qui omessi i nomi: nessun dato personale nel deposito). Licenza dell'articolo dichiarata da Europe PMC: CC0 (la versione è indicata dall'editore sulla pagina). Abstract riportato senza modifiche al contenuto, con attribuzione; deposito marcato CC0. Letto il 2026-11-05T22:42:47.959Z tramite l'API REST ufficiale di Europe PMC (EMBL-EBI), nel rispetto del robots.txt e del crawl-delay.